Heartbeam (BEAT) Investor presentation summary

Market need and clinical gap

• Heart attack detection requires 12-lead ECG, typically only available in clinical settings, leaving a gap for at-home detection and timely intervention.

• Patient delays before hospital arrival are a major driver of poor outcomes and increased costs in cardiac events.

• Current consumer ECG devices lack the spatial orientation needed for reliable ischemia detection outside hospitals.

Platform and technology

• The platform delivers a cable-free, synthesized 12-lead ECG for at-home use, powered by patented 3D signal collection technology.

• Over 25 patents protect the unique approach, including a credit card-sized device that captures heart signals in three dimensions.

• Personalized algorithms convert 3D signals into physician-ready 12-lead ECGs in real time.

• FDA 510(k) clearances obtained for arrhythmia detection and 12-lead synthesis algorithm in 2024 and 2025.

Market opportunity and strategy

• Addressable market exceeds 50 million patients and $40B in the U.S. alone, spanning concierge, preventive, and broader telehealth segments.

• Initial focus is on concierge and preventive cardiology, targeting 1.5M patients with high willingness to pay and early adoption potential.

• Expansion plans include broader patient pay, telehealth, and national chains, leveraging a scalable, high-margin subscription model.

• Strategic partnerships, such as with ClearCardio and Mount Sinai, support adoption and AI development.